Asset
EFTILAGIMOD ALFA
Immutep Limited American Depositary Shares
Revenue
No revenue reported in loaded filings.
Clinical trials (5)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02614833 | phase2 | completed | 2015-12-01 | 2020-03-01 | Immutep S.A.S. | IMP321 (Eftilagimod Alpha) as Adjunctive to a Standard Chemotherapy Paclitaxel Metastatic Breast Carcinoma |
| NCT00351949 | phase1 | completed | 2005-09-01 | 2008-08-01 | Immutep S.A.S. | IMP321 Phase 1 Trial in Metastatic Renal Cell Carcinoma (MRCC) |
| NCT00349934 | phase1 | completed | 2006-07-01 | 2009-11-01 | Immutep S.A.S. | IMP321 Plus First-line Paclitaxel in Metastatic Breast Carcinoma |
| NCT02676869 | phase1 | completed | 2016-04-01 | 2019-08-01 | Immutep Australia Pty. Ltd. | Phase 1 Study of IMP321 (Eftilagimod Alpha) Adjuvant to Anti-PD-1 Therapy in Unresectable or Metastatic Melanoma |
| NCT00354263 | phase1 | completed | 2005-04-01 | 2005-09-01 | Immutep S.A.S. | Phase I Study of IMP321 Given Alone or as an Adjuvant to a Reference Flu Antigen |
FDA applications (0)
This company has no applications containing this asset.